Andrew L. Kung, MD, PhD is a physician-scientist and Chair of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center (MSKCC), where he oversees the clinical, research and educational missions of the Department. His clinical expertise is in cancer genomics, precision medicine and stem cell transplantation. His research laboratory is focused on identifying the causes of pediatric cancers and developing new treatments to benefit children and adolescents with cancer. Dr. Kung received his M.D. and Ph.D. degrees at Stanford University School of Medicine and completed post-graduate medical training as a pediatric oncologist at Boston Children’s Hospital and the Dana-Farber Cancer Institute. He served as a faculty member at Harvard Medical School for 18 years and was recruited to New York City as the Director of the Division of Pediatric Hematology/Oncology at Columbia in July 2012. In July 2016, he was recruited to MSKCC to lead one of the largest pediatric oncology programs in the world. Working with his colleagues, Dr. Kung takes a translational approach to cancer research, integrating diverse disciplines with the ultimate goal of clinical translation. The research in his lab focuses on identifying new targets for anticancer drugs, the genetics of cancer, and the development of innovative therapies that target the molecular abnormalities fueling cancer growth. Studies from his lab have led to new clinical trials for leukemia, brain tumors and sarcomas.